{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:06:27Z","timestamp":1790899587379,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.virol.2024.110051","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T23:49:15Z","timestamp":1709855355000},"page":"110051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The investigation of the dynamics of changes in neutralizing antibody titers against type 5 adenovirus in the context of vaccination against a new coronavirus infection"],"prefix":"10.1016","volume":"594","author":[{"given":"I.V.","family":"Amosova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-8714","authenticated-orcid":false,"given":"T.A.","family":"Timoshicheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Kadyrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.A.","family":"Zabrodskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.S.","family":"Vakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Grudinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.V.","family":"Dzytseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Khmelevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Lioznov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.virol.2024.110051_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-022-00566-x","article-title":"Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination","volume":"7","author":"Byazrova","year":"2022","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.virol.2024.110051_bib2","first-page":"111","article-title":"Development of vaccines based on adenoviral vectors: a review of foreign clinical studies (Part 1)","volume":"vol. 19","author":"Cherenova","year":"2017"},{"key":"10.1016\/j.virol.2024.110051_bib3","unstructured":"clinicaltrials.gov. (2023, May 28). Https:\/\/Clinicaltrials.Gov\/Ct2\/Results?Term=adenovirus&Search=Apply&age_v=&gndr=&type=Intr&rslt=."},{"key":"10.1016\/j.virol.2024.110051_bib4","article-title":"Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action","volume":"vol. 6","author":"Heinz","year":"2021"},{"issue":"4","key":"10.1016\/j.virol.2024.110051_bib5","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ymthe.2006.03.024","article-title":"Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system","volume":"14","author":"Kiang","year":"2006","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.virol.2024.110051_bib6","first-page":"763","article-title":"Microneutralization reaction compared to hemagglutination inhibition assay to evaluate immunogenicity of influenza vaccines and influenza diagnostics","volume":"9","author":"Krivitskaya","year":"2019","journal-title":"Russian Journal of Infection and Immunity = Infektsiya i Immunitet"},{"key":"10.1016\/j.virol.2024.110051_bib7","unstructured":"laboratory_diagnostics https:\/\/www.influenza.spb.ru\/system\/epidemic_situation\/laboratory_diagnostics\/. (2023, May 28)."},{"issue":"3 March","key":"10.1016\/j.virol.2024.110051_bib8","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia","volume":"18","author":"Lioznov","year":"2023","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.virol.2024.110051_bib9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A review of 65 years of human adenovirus seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expet Rev. Vaccine"},{"issue":"10","key":"10.1016\/j.virol.2024.110051_bib10","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1128\/JVI.79.10.6516-6522.2005","article-title":"Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates","volume":"79","author":"Santra","year":"2005","journal-title":"J. Virol."},{"issue":"45","key":"10.1016\/j.virol.2024.110051_bib11","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1016\/j.vaccine.2018.09.031","article-title":"Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy","volume":"36","author":"Sayedahmed","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2024.110051_bib12","first-page":"38","article-title":"Human adenovirus infections in pediatric population - an update on clinico\u2013pathologic correlation","volume":"vol. 45","author":"Shieh","year":"2022"},{"issue":"1","key":"10.1016\/j.virol.2024.110051_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.55.091902.104344","article-title":"Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors","volume":"55","author":"Shiver","year":"2004","journal-title":"Annu. Rev. Med."},{"issue":"7","key":"10.1016\/j.virol.2024.110051_bib14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1134\/S0003683822070079","article-title":"The diagnostic potential of monoclonal antibodies to adenovirus","volume":"58","author":"Timoshicheva","year":"2022","journal-title":"Appl. Biochem. Microbiol."},{"issue":"1","key":"10.1016\/j.virol.2024.110051_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.15789\/2220-7619-IAO-1693","article-title":"Immunograph-based analysis of the influenza A(H1N1)pdm09 vaccine strain immunogenicity in the pandemic and post-pandemic period (2009\u20132014)","volume":"12","author":"Vakin","year":"2022","journal-title":"Russian Journal of Infection and Immunity"},{"issue":"10249","key":"10.1016\/j.virol.2024.110051_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"10240","key":"10.1016\/j.virol.2024.110051_bib17","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224000722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224000722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T01:54:49Z","timestamp":1762221289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682224000722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":17,"alternative-id":["S0042682224000722"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2024.110051","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The investigation of the dynamics of changes in neutralizing antibody titers against type 5 adenovirus in the context of vaccination against a new coronavirus infection","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2024.110051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110051"}}